Last updated: August 5, 2025
Introduction
Patent CN1726035, filed in China, pertains to a pharmaceutical invention, with details reflecting China's growing emphasis on drug innovation and intellectual property rights (IPR). This analysis explores the patent’s scope, claims, the underlying inventive concept, and positions it within the broader Chinese pharma patent landscape. Understanding this patent aids stakeholders—pharmaceutical companies, IP strategists, and legal practitioners—in assessing its competitive value and technological significance.
Overview of Patent CN1726035
-
Application and Publication Details:
Filed on November 22, 2004, and published in 2007, CN1726035 likely claims a novel compound, formulation, synthesis method, or therapeutic application. The patent’s priority indicates early-stage innovation during a period of transitioning Chinese patent law towards stronger pharmaceutical protections.
-
Type and Legal Status:
The patent falls under a utility patent (likely a Chinese invention patent), offering 20-year protection from the filing date, subject to maintenance fees. An examination process likely concluded, confirming its validity and enforceability.
Scope of the Patent
The patent’s scope revolves around a specific chemical entity or medicinal formulation designed for therapeutic use. While the full claims text requires review, typical dimensions include:
-
Novel Chemical Compound or Derivative:
The core focus is probably on a unique molecular structure with optimized pharmacological activity.
-
Pharmaceutical Formulations and Dosage Forms:
The patent may specify formulations enhancing bioavailability, stability, or patient compliance.
-
Synthesis Methodologies:
Novel synthesis routes that improve efficiency, reduce costs, or enhance purity are also plausible claims.
-
Therapeutic Indications:
The claims may extend to specific medical uses, such as treatment of certain cancers, infectious diseases, or chronic conditions.
The scope's breadth affects patent enforceability and competition: broader claims encompass a wider range of analogous compounds; narrower claims provide specific protection but are easier to design around.
Claims Analysis
The core claims of CN1726035 are central to understanding its patentability and infringeability.
-
Independent Claims:
Likely define the chemical structure or formulation in a broad manner, establishing the legal boundary. For example, a claim might specify a chemical compound with particular substituents or a pharmacologically active moiety.
-
Dependent Claims:
Specify particular embodiments—such as specific substitutions, dosage ranges, or synthesis processes—that refine the scope and provide fallback positions if broader claims are invalidated.
-
Claim Prioritization:
Given the typical strategy, the primary claims aim at broad protection to cover a spectrum of related compounds or formulations, with narrower claims providing specificity.
-
Potential Patentable Features:
Novel chemical bonds, stereochemistry, or unique combinations likely constitute the inventive step. Claims covering these features are critical for defending the patent’s validity.
Inventive Step and Patentability
The patent’s inventive merit hinges on:
- Demonstration of unexpected therapeutic advantages over prior art.
- Overcoming known synthesis challenges through innovative methods.
- Targeting a previously unexploited therapeutic pathway or chemical scaffold.
In China, patent examiners rigorously evaluate novelty, inventive step, and industrial applicability, relying heavily on existing chemical and medical literature. The patent’s validity may ultimately depend on clear distinctions from prior art, especially from early Chinese and international patents in similar drug classes.
Patent Landscape and Competitive Positioning
-
Chinese Patent Environment:
China’s patent system has significantly strengthened since 2000, with increased focus on pharmaceutical inventions. Chinese patent offices employ comprehensive prior art searches, and patent examiners often scrutinize chemical novelty and inventive step rigorously.
-
Domestic Patent Filings:
The patent aligns with China’s push toward indigenous innovation, especially in biopharmaceuticals and chemical drugs. Many Chinese companies focus on patenting modified compounds and new formulations to secure market exclusivity.
-
International Positioning:
Although CN1726035 is a Chinese patent, its scope may influence or complement patent filings in jurisdictions like the US, Europe, or Japan. The value of this patent in global markets depends on corresponding filings and enforceable claims.
-
Patent Family and Related Patents:
Likely, the patent belongs to a family of applications, including foreign counterparts, which expand protection and mitigate risks of infringement.
Potential Challenges and Opportunities
-
Challenges:
- Prior art resemblances, especially in chemical scaffolds, may challenge patent validity.
- Patent examiners may require specific inventive step evidence, particularly if similar compounds existed before.
- Patent infringement risks increase if competitors develop similar compounds with slight modifications, emphasizing the need for well-drafted claims.
-
Opportunities:
- Leveraging strong, broad claims to establish market exclusivity.
- Positioning the patent within a comprehensive IP strategy, including regulatory data protections and later-filed patents on improvements.
- Exploring licensing, partnership, or infringement litigation based on patent scope.
Legal and Commercial Significance
This patent is crucial for innovator companies aiming to protect key therapeutic compounds in China, a rapidly growing pharmaceutical market. Its strength and scope directly influence market entry strategies, R&D investment decisions, and partnership negotiations.
Key Takeaways
- CN1726035 appears to represent a strategic patent covering a novel drug compound or formulation, with claims designed to secure broad protection.
- The patent’s strength depends on the novelty, inventive step, and scope of its claims—particularly its chemical structure and therapeutic application.
- In China’s evolving patent landscape, such patents are vital for protecting innovation, but require continuous monitoring to defend against challenges and design around.
- Understanding the patent’s positioning within a comprehensive patent landscape—including potential family members—is key to maximizing commercial value.
- Stakeholders should assess the scope critically, considering potential challenges from prior art and ensuring appropriate patent claims drafting and strategic patent family planning.
FAQs
-
What is the main innovation of CN1726035?
It likely covers a novel chemical compound or formulation with specific therapeutic purposes, designed to improve efficacy or manufacturing.
-
How broad are the claims typically in such pharmaceutical patents?
Claims can range from broad structural classes to specific compounds; broader claims provide wider protection but are harder to defend successfully.
-
Can this patent block competitors from developing similar drugs?
Yes, if the claims are sufficiently broad and valid, it can prevent competitors from manufacturing or selling similar compounds claiming infringement.
-
What are the main challenges in defending such patents in China?
Overcoming prior art challenges, demonstrating inventive step, and ensuring claim clarity are key hurdles in Chinese patent proceedings.
-
Is CN1726035 enforceable outside China?
No, it’s valid only within China unless corresponding foreign patents have been filed; enforcement requires jurisdiction-specific legal actions.
References
[1] State Intellectual Property Office of China (SIPO). Patent CN1726035 Document.
[2] Chinese Patent Law (latest revision).
[3] World Intellectual Property Organization (WIPO). Patent landscape reports on Chinese pharmaceuticals.
[4] Tsinghua University IP Law Review. Analysis of Chinese drug patent application standards.
[5] Market intelligence reports from Frost & Sullivan and IQVIA on R&D trends in Chinese pharma.
Conclusion
The patent CN1726035 exemplifies China's patent strategy to foster innovation in the pharmaceutical sector. Its scope and claims form the backbone of market protection and competitive positioning for the patent holder. As China’s patent laws and industry evolve, continuously monitoring patent landscape dynamics and strategic claim management will remain essential for maximizing patent value and safeguarding pharmaceutical innovations.
